Table 1 Mean total number of drug prescriptions per GP per year, standardised per 1000 enlisted patients for the total intervention region versus a matched control group
|  | Desired direction of drug | pre | Short term | Δ short term | Long term | Δ Long term | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | I (n = 53) | C (n = 54) | I (n = 53) | C (n = 54) | I (n = 53) | C (n = 54) | I (n = 53) | C (n = 54) | I (n = 53) | C (n = 54) |
Drug indicators | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Antibiotics2 | ↓ | 639 (551,833) | 491 (388,595) | 667 (532,812) | 489 (386,601) | 3 (-56,70) | 1 (-30,40) | 652 (512,767) | 486 (405,602) | -20 (-91,65) | -6 (-40,43) |
Chinolones2 | ↓↓ | 37 (22,53) | 24 (13,34) | 36 (23,48) | 22 (12,33) | 1 (-12,9) | 1 (-6,5) | 34(27,44) | 21 (14,31) | -4 (-10,4) | -1 (-7,5) |
Nitrofurantoin1 | ↑ | 26 (19,33) | 33 (27,39) | 27 (22,33) | 33 (26,40) | 1 (-4,6) | 0 (-3,3) | 31(25,37) | 37 (30,43) | 5 (-1,10) | 4 (0,8) |
Trimethoprim1 | ↑ | 27 (20,33) | 24 (18,30) | 29 (21,36) | 24 (18,29) | 2 (-2,6) | -1 (-3,2) | 26(20,32) | 22 (17,28) | -1 (-6,5) | -2 (-6,2) |
Amoxicillin with clav.acid2 | ↓ | 31 (24,51) | 27 (18,41) | 31 (19,46) | 26 (17,41) | -3 (-10,8) | -1 (-8,5) | 28(18,45) | 28 (19,37) | -2 (-16,11) | 0 (-10,5) |
Amoxicillin2 | ↓ | 76 (48,126) | 62 (37,94) | 69 (34,112) | 67 (44,100) | -6 (-53,20) | -1 (-12,8) | 54(38,104) | 58 (37,109) | -14 (-35,2) | -2 (-17,13) |
Doxycyclin1 | ↓ | 133 (109,156) | 83 (71,95) | 126 (104,148) | 79 (68,90) | -7 (-20,6) | -4 (-10,2) | 114(93,135) | 73 (62,84) | -19 (-35, -3) | -10 (-16, -4) |
Mupirocin2 | ↓ | 5 (2,20) | 5 (1,10) | 5 (2,13) | 5 (1,16) | -1 (-6,1) | 1 (-2,5)* | 5(2,11) | 3 (1,12) | 0 (-6,2) | 0 (-3,2) |
Cholesterol synthesis inhibitors (Statins) 1 | ↑↑ | 182 (154,209) | 140 (115,164) | 219 (188,249) | 162 (136,189) | 37 (28,46) | 22 (16,29) | 294 (248,339) | 194 (164,224) | 112 (87,137) | 54 (41,66)* |
Asthma & COPD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Long-term beta2-sympaticomimetics1 | ↑ | 40 (33,46) | 40 (32,47) | 37 (31,43) | 37 (30,44) | -3 (-6, -1) | -3 (-6,0) | 36(29,42) | 31 (25,38) | -4 (-8,0) | -8 (-13, -4) |
Asthma | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Short-term beta2-sympaticomimetics2 | ↓ | 28 (21,44) | 29 (19,35) | 29 (18,39) | 28 (19,41) | 0 (-6,6) | 2 (-3,7) | 28(19,36) | 27 (20,38) | -4 (-8,1) | -1 (-8,5) |
Inhaled corticosteroids2 | ↑ | 21 (14,33) | 19 (13,28) | 19 (10,28) | 21 (13,33) | -3 (-8,0) | -1 (-5,4) | 14(9,23) | 18 (11,26) | -7 (-11, -2) | -2 (-10,1) |
COPD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Short-term beta2-sympaticomimetics1 | - | 62 (54,70) | 42 (34,49) | 61 (52,70) | 42 (34,49) | -2 (-6,3) | 0 (-3,4) | 59(50,69) | 36(29,42) | -3(-8,2) | -6 (-10, -2) |
Inhaled corticosteroids1 | ↓ | 55 (46,64) | 51 (42,59) | 51 (42,60) | 48 (39,57) | -5 (-8, -1) | -3 (-6,1) | 41(33,48) | 40(32,48) | -15(-20, -10) | -10 (-15, -6) |